Navigation Links
Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241

ivation. The studies also identified two other proteins, MEKK1 and caspase-3, which mediate the cell-killing effects of INGN 241.

Based on these results, it is anticipated that the combination of INGN 241 and inhibitors of NF-kB will have an enhanced therapeutic effect and be suitable for clinical evaluation.

About INGN 241

INGN 241 is being tested in a Phase 2 clinical trial for patients suffering from advanced melanoma and in a Phase 3 clinical trial in combination with radiation therapy in solid tumors. The mda-7 gene is the active component of INGN 241 and was discovered in the laboratory of Dr. Paul B. Fisher, professor of clinical pathology at Columbia University. Introgen holds an exclusive worldwide sublicense to the Columbia University rights for all gene therapy applications from GlaxoSmithKline.

About Introgen

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Introgen holds a licensing agreement with M. D. Anderson Cancer Center to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. The University of Texas Board of Regents owns stock in Introgen. These arrangements are managed in accordance with M. D. Anderson's conflict of interest policies.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen'
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
(Date:1/7/2009)...y 7 Circassia Ltd, a specialty,bi...tical care, today,announced that following succes...oleroMune(R) anti-allergy technology, the company ...er phase II clinical trial in cat allergy. The,st...0 patients with confirmed,cat allergies, and all ...
(Date:1/6/2009)...ewswire-USNewswire/ -- Sequella, Inc., a clinical-...s of epidemic potential, announced today that SQ10...berculosis (TB), was the first drug approved for e...ract to Dynport Vaccine Company LLC and Quintiles ...al Institute of Allergy and Infectious Diseases (N...
(Date:1/5/2009)...PRNewswire-FirstCall/ -- Micromet, Inc.,(Nasdaq: ...ovel, proprietary,antibodies for the treatment of...ovides an outlook on key events anticipated for th...e an update on its research and development,progr...to 16, 2009: Update on several preclinical BiTE an...
(Date:12/27/2008)...23 Warner Chilcott Limit...ts subsidiaries and Mayne Pharma International Pty...ave filed lawsuits against each of Mutual Pharmace...cals Inc. ("Mylan") and Impax Laboratories, Inc. (...f New Jersey for infringement of Mayne,s U.S. Pate...
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3Sticky questions tackled in gecko research 1692 1Sticky questions tackled in gecko research 1692 2American Lung Association Offers Biodiesel Scholarship to Minnesota High School Seniors 8632 1Alegent com Goes Mobile 8628 1Alegent com Goes Mobile 8628 2Nick at Nite Asks Families to Kick a Bad Habit Pick a Good One in 2008 8624 1Nick at Nite Asks Families to Kick a Bad Habit Pick a Good One in 2008 8624 2Nick at Nite Asks Families to Kick a Bad Habit Pick a Good One in 2008 8624 3
... the ASCO Cancer Conference, NORTH HOLLYWOOD, Cali... International Myeloma Foundation (IMF)-supporting...pport for myeloma patients,families, researchers ...up to a Phase 3 multi- national clinical trial sho...roves the probability of,survival by 41%. The foll...
...-Agent Activity Support Development of Panzem(R),N...forme, ROCKVILLE, Md., June 05, 2007 /PRNewswire-F...rmaceutical company developing,therapeutics for th...nnounces the presentation of results of a single-a...ients with glioblastoma,multiforme (GBM). The data...
Other Medicine Technology:Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma 2Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 2Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 3Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study,Presented at ASCO 4
(Date:1/8/2009)...Newswire-FirstCall/ -- Medivation, Inc.,(Nasdaq: ...esident and chief,executive officer, will present...ence on Wednesday, January 14, at 10:00 a.m. Pacif...ancisco. , Dr. Hung will provide an overvie...rams for Dimebon for Alzheimer,s and Huntington,s ...
(Date:1/8/2009)...g traditional risk factors, experts say , ...ular signs -- or "biomarkers" -- of inflammation m...s a person,s risk of stroke, new research says. ,...these markers does not change things much," said s...t the Methodist DeBakey Heart & Vascular Cente...
(Date:1/8/2009)...wswire-FirstCall/ -- Heska Corporation (Nasdaq: ... What: Heska Corporation Invites You to Joi...008 Earnings Conference Call on the Web, Whe..., Where: www.heska.com (click on the Q4 and ... the front page of this website)., How: ...
(Date:1/8/2009)...ter Healthcare Corporation will create a multidisc... entities announced today. , Under the three-yea...ollaboration projects at Northwestern. Funding lev...on, and Baxter will determine specific project fun...Baxter,s diversified business model, activities wi...
Breaking Medicine News(10 mins):Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2Health News:Baxter and Northwestern University partner to target new life sciences projects 2
... is the fastest growing disability in the United S...ch up. One out// of every 166 children is diagnose...c cancer, diabetes and AIDS combined. The Autism ... and Training (ASSERT) program at Utah State Unive...
... looking to lose those extra pounds have been told...ill bring about the best results//. Not so, says n...s effective as dieting plus exercise. The key is i...t calories can be lost effectively by either dieta...
...ing to a latest study, blood letting in patients w...f carried out at a young age//. This finding was p...merican Medical Association. Iron deposit in the ...eloping heart ailments. Hence reducing iron from t...
...from Naples, New York who was diagnosed with lung ...enk who is a former Marine// is currently sufferin...ven him a year or at the maximum eighteen months o...his lottery. But the irony that is accompanying th...
Other Medicine News:Health News:Autism Expert Creates Innovative Intervention Program 2Health News:Autism Expert Creates Innovative Intervention Program 3Health News:Shedding Pounds from Diet or Exercise—Take Your Pic 2Health News:Shedding Pounds from Diet or Exercise—Take Your Pic 3
...White Sun light source offers the industry standar...o Kelvin color temperature at a lower price. A uni...Sun to be used with Olympus, Storz, ACMI/Circon an...s light output LED and re-settable bulb timer. The...
...NGAL ELISA Kit is intended for determination of hu...ine), tissue extracts or culture media., NGAL (n...atically increased, especially in urine, as early ... repair processes. NGAL expression in plasma or ur...
...Dual Light Head is clearly the favorite for most s... arms, the dual light heads rotate freely about th...nlimited positioning. Engineered construction prev...es ranging from minimally invasive through trauma ...
... configuration offers all the performance of a maj...ctly for use in Outpatient Settings, Minor Procedu...ng two single lights either side of the OR table i...hen combining Flat Screen LCD Monitors with the li...
Medicine Products: